Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Epithelial Cancer
Research on epithelial cancer described by scientists at University of California
March 13th, 2008
"Pretargeted radioimmunotherapy (RIT) is a promising approach to increase the therapeutic index of RIT for malignant solid tumors. For pretargeted. RIT of epithelial cancers, such as breast and prostate, mucin 1 (MUC1), the epithelial mucin, was chosen as a target antigen (Ag)," scientists writing in the Quarterly Journal of Nuclear Medicine and Molecular Imaging report. "Overexpression, hypoglycosylation and loss of apical. distribution on the cellular membrane distinguish the tumor associated MUC1 from normal MUC1. These characteristics of MUC1, best known in breast cancer, were validated in prostate cancer. The multivalent bispecific MUC1 pretargeting molecule...
Source: Women's Health Weekly (2008-03-13)
|
